Evidence map›Paper›PMID 40699512›Full record

ReviewJournal of cardiovascular translational research2025

Nanoparticles For Rescue: Innovative Therapeutic Strategy For Cardiac Repair After Myocardial Infarction.

Yi-An Mao, Rui Wang, Xiaozhou Shi, Yanjia Jin, Zihan Pan, Emeli Chatterjee, Guoping Li, Xuerui Chen, Hongdong Wang, Jizong Jiang and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Cardio Protective Role of Graphene-based FeCell biochemistry and biophysics · 2026
    Article
  3. Cardio Protective Role of Graphene-based FeCell biochemistry and biophysics · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi-An Mao *Joint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Rui Wang *Joint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Xiaozhou ShiJoint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Yanjia JinJoint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Zihan PanQianweichang College, Shanghai University, Shanghai, 200444, China.
Emeli ChatterjeeCardiovascular Division of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Guoping LiCardiovascular Division of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Xuerui ChenJoint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China.
Hongdong WangSchool of Mechatronic Engineering and Automation, Shanghai University, Shanghai, 200444, China. whd20@shu.edu.cn.
Jizong JiangJoint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China. jiangjizong@shu.edu.cn.
Junjie XiaoJoint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), School of Life Science, Shanghai University, Shanghai, 200444, China. junjiexiao@live.cn.ORCID 0000-0002-9202-0003

Funding

National Key R&D Program of China Grant 2022YFA1104500National Natural Science Foundation of China 82020108002National Natural Science Foundation of China 82225005Science and Technology Commission of Shanghai Municipality 23410750100
6 · The paper itself

Abstract

Myocardial infarction (MI), is a leading cause of global mortality, marked by cardiomyocyte death. This takes place as a result of ischemic injury, the detrimental impacts of oxidative stress, and inflammatory responses. Conventiona pharmacological interventions, are unfortunately limited by a relatively low targeting efficiency and the inability to reverse the fate of cardiomyocyte death. Recent advances in nanotechnology have led to the development of multifunctional nanoparticles, offering innovative solutions to effectively address these complex challenges. These nanoscale platforms have the remarkable capability to enable targeted drug delivery, precisely regulate the microenvironment, and facilitate real-time monitoring of the cardiac repair processes. This development represents a substantial paradigm shift in the treatment of MI. This review integrates the crucial findings obtained from the recent studies focusing on nanoparticle-based strategies for multifunctional cardiac repair after MI, aiming to explore the potential of nanoparticles in the treatment of MI.

Indexed as

Cardiovascular AgentsMyocardial InfarctionMyocardiumMyocytes, CardiacNanoparticle Drug Delivery SystemNanoparticlesRegenerationAnimalsHumansRecovery of FunctionTreatment OutcomeCardiovascular AgentsNanoparticle Drug Delivery SystemCardiac repairDelivery systemMyocardial infarctionNanoparticleTargeted therapy

Identifiers

PMID40699512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.